The Chemours Company (NYSE:CC) Position Raised by Lavaca Capital LLC

Lavaca Capital LLC lifted its stake in shares of The Chemours Company (NYSE:CC) by 2.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,658 shares of the specialty chemicals company’s stock after acquiring an additional 641 shares during the quarter. Lavaca Capital LLC’s holdings in Chemours were worth $648,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Appian Way Asset Management LP acquired a new stake in shares of Chemours in the first quarter worth $7,575,000. Price T Rowe Associates Inc. MD raised its position in shares of Chemours by 3.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 91,345 shares of the specialty chemicals company’s stock worth $2,399,000 after acquiring an additional 2,932 shares during the last quarter. Edgestream Partners L.P. acquired a new position in Chemours during the 1st quarter valued at about $1,228,000. Mitsubishi UFJ Trust & Banking Corp lifted its stake in shares of Chemours by 169.3% in the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 35,105 shares of the specialty chemicals company’s stock valued at $1,009,000 after purchasing an additional 22,067 shares during the period. Finally, Private Management Group Inc. increased its stake in shares of Chemours by 66.1% in the 1st quarter. Private Management Group Inc. now owns 447,715 shares of the specialty chemicals company’s stock valued at $11,757,000 after acquiring an additional 178,145 shares during the last quarter. 76.26% of the stock is owned by hedge funds and other institutional investors.

Chemours Stock Down 1.9 %

Shares of CC stock traded down $0.47 on Monday, hitting $23.85. The stock had a trading volume of 762,443 shares, compared to its average volume of 1,584,339. The stock has a market cap of $3.55 billion, a price-to-earnings ratio of -10.99 and a beta of 1.80. The company has a debt-to-equity ratio of 5.26, a current ratio of 1.61 and a quick ratio of 0.99. The business has a 50 day moving average of $24.14 and a 200 day moving average of $26.55. The Chemours Company has a 12-month low of $15.10 and a 12-month high of $37.83.

Chemours (NYSE:CC) last released its quarterly earnings data on Tuesday, April 30th. The specialty chemicals company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.07. Chemours had a negative net margin of 5.51% and a positive return on equity of 46.67%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.35 billion. During the same period in the previous year, the business earned $0.98 EPS. Chemours’s revenue was down 12.1% compared to the same quarter last year. As a group, analysts expect that The Chemours Company will post 1.81 EPS for the current year.

Chemours Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 13th. Stockholders of record on Thursday, August 15th will be paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 4.19%. The ex-dividend date of this dividend is Thursday, August 15th. Chemours’s dividend payout ratio (DPR) is presently -46.08%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on CC shares. UBS Group raised Chemours from a “neutral” rating to a “buy” rating and raised their price target for the stock from $28.00 to $30.00 in a research report on Tuesday, July 9th. Barclays dropped their price target on shares of Chemours from $32.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 2nd. BMO Capital Markets upgraded Chemours from an “underperform” rating to an “outperform” rating and lifted their target price for the stock from $19.00 to $34.00 in a research note on Tuesday, April 9th. Finally, Mizuho started coverage on shares of Chemours in a research note on Friday, June 7th. They issued a “neutral” rating and a $25.00 price target on the stock. Six analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $30.38.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.